Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
322.64 K
Value Traded
7.38 M
Short % Float
7.17%
-11.85%Week
-36.43%1 Month
-23.42%3 Month
+71.51%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
643.94 M
EPS (TTM)
-7.57
P/E Ratio
-
Ent. Value
457.50 M
Total Shares
25.84 M
Float Shares
18.39 M
Insiders
28.82%
Institutions
48.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
FTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Faeth Therapeutics, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Faeth Therapeutics, Inc. Common Stock
167Total events
8Upcoming
33Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationPIKTORDesignation
FDA granted Fast Track designation to PIKTOR plus paclitaxel
advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterationsource ↗
◆Poster PresentationPIKTORPresentation
Poster presentation of PK/PD modeling at STOP Cancer conference
second-line advanced endometrial cancersource ↗
●Timing GuidancePresentation
Company name change to Faeth Therapeutics and ticker change to FTH
◆Timing GuidancePresentation
Stockholder vote scheduled for conversion of Series B Preferred Stock
▲Corporate ApprovalCorporate
Stockholders approved conversion of Series B preferred stock into common stock
●Management ChangeCorporate
Anand Parikh appointed Chairman, President and CEO; Brian Stephenson appointed CFO; board strengthened with Stephen M. Hahn and Saira Ramasastry
▲First Patient DosedPIKTORTrial
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer
HR+/HER2- advanced breast cancersource ↗
▲First Patient DosedPIKTORTrial
First patient dosed in Phase 1b/2 PIK-101 trial of PIKTOR in HR+ breast cancer
HR+/HER2- advanced breast cancersource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss acquisition and financing
▼Equity OfferingCorporate
Private placement closed concurrently with acquisition of Faeth, raising ~$200M gross proceeds
●Trial InitiationsolnerstotugTrial
Planned initiation of Phase 2 study for solnerstotug
PD-(L)1 resistant tumorssource ↗
▼Program DiscontinuationsolnerstotugCorporate
Discontinuation of solnerstotug development
cancersource ↗
▼Trial DiscontinuedsolnerstotugTrial
Orderly wind-down of ongoing Phase 1/2 clinical trial
cancersource ↗
◆Oral PresentationsolnerstotugPresentation
Mini oral session at ESMO Congress 2025 presenting Phase 1/2 dose expansion results for solnerstotug
PD-(L)1 resistant tumorssource ↗
▲Topline ReadoutsolnerstotugClinical Data
Phase 1/2 dose expansion topline results: 6-month PFS 50% at 15 mg/kg in PD-(L)1 resistant patients
PD-(L)1 resistant tumorssource ↗
▲Runway Guidance UpdateCorporate
Cash runway into Q4 2025, funding midway into Phase 2 studies of SNS-101
▲Enrollment CompletesolnerstotugTrial
Dose expansion enrollment complete
advanced solid tumorssource ↗
▲Enrollment CompletesolnerstotugTrial
Achieved target enrollment in dose expansion cohort
advanced solid tumorssource ↗
▲Topline ReadoutsolnerstotugClinical Data
Preliminary dose expansion data for solnerstotug in PD-(L)1 resistant tumors
PD-(L)1 resistant tumorssource ↗
▲Oral PresentationsolnerstotugPresentation
Preliminary dose expansion data presented at investor webcast
advanced solid tumorssource ↗
◆Full ResultssolnerstotugClinical Data
Full data for Phase 1/2 dose expansion cohort expected by year-end 2025
advanced solid tumorssource ↗
◆Topline ReadoutSNS-101Clinical Data
SNS-101 Phase 1/2 dose expansion clinical data expected in first half of 2025
advanced solid tumorssource ↗
◆Topline ReadoutSNS-101Clinical Data
Initial Phase 1 expansion data expected by year-end 2024
solid tumorssource ↗
▼Restructuring LayoffsCorporate
Organizational restructuring to reduce headcount and focus on SNS-101
Past FDA Catalysts and PDUFA Decisions
How FTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$83M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 70%
Micro Cap(rank 461 of 658)
Percentile Rank
Faeth Therapeutics, Inc. Common Stock faces pipeline headwinds (30/100), with $208M risk-adjusted pipeline value, led by Serabelisib in HR+ HER2- Breast Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Serabelisib Small moleculeNCT07558733 | HR+ HER2- Breast Cancer | Phase 1 | RECRUITING | 32 | May 1, 2033 |
Clinical Trial Results
Readouts, endpoints and source filings for every FTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| solnerstotug | PD-(L)1 resistant tumors | Phase 1/2 | 2025-10-17 | 6 month PFS at 15 mg/kg: 50%; 6 month PFS at 3 mg/kg: 24%; overall 6 month PFS among 'hot tumor' patients: 37%; clinical responses at 15 mg/kg: 6; clinical responses in PD (L)1 resistant tumors: 5Read More | Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - 6-month progression-free survival (PFS) of Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STEPHENSON BRIAN COfficer (Chief Financial Officer) | Buy | 4,400 46,088 held | $23.40 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 0.3 % | 36.10 M | 1.44 M |
FTH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FTH ranks across every disease it competes in
Competitive Position is a premium feature
See how FTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFTH News
-FTH
Sep 17, 2026Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Faeth Therapeutics has appointed Dr. Karen Vousden to its Board of Directors, effective September 11, 2026. Dr. Vousden has been instrumental in shaping the company's scientific direction and has served as a trusted advisor since its founding. Her expertise is expected to enhance the company's strategic initiatives in cancer treatment.
Read more →-FTH
Sep 8, 2026Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Faeth Therapeutics has announced a virtual key opinion leader event scheduled for October 6, 2026. The event will feature Dr. Marcus Goncalves from NYU Langone Health, who will discuss the PAM pathway in relation to endometrial cancer. This initiative highlights the company's commitment to advancing cancer treatment through expert collaboration.
Read more →-FTH
Sep 1, 2026▲ +5.3%on this news· ran to +22% by day 3
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Faeth Therapeutics, a clinical-stage oncology company, has announced its participation in two upcoming investor conferences. The events include the Wells Fargo 21st Annual Healthcare Conference and the Citi Biopharma Back to School Summit. This engagement aims to showcase their lead program, PIKTOR, and connect with potential investors.
Read more →-FTH
Aug 28, 2026Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics has granted options to purchase 94,000 shares of common stock to three new employees. This decision was made by the Compensation Committee as part of the company's 2026 Inducement Plan, effective August 25, 2026. The move aims to attract talent and support the company's growth strategy.
Read more →-FTH
Aug 17, 2026Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Faeth Therapeutics has received Fast Track designation from the FDA for its PIKTOR combination therapy, which includes sapanisertib and serabelisib with paclitaxel. This designation is specifically for treating patients with advanced or recurrent endometrial cancer that have specific genetic alterations. The Fast Track status aims to expedite the development and review process for this promising treatment.
Read more →-FTH
Aug 14, 2026▲ +13.3%on this newsshared move
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Faeth Therapeutics has announced the appointment of Deepak Tiwari as Senior Vice President of Technical Operations and Matt Biegler as Senior Vice President of Investor Relations. These appointments are part of the company's strategy to strengthen its leadership team in preparation for upcoming clinical milestones related to its PIKTOR program.
Read more →-FTH
Aug 7, 2026Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Faeth Therapeutics will present important PK/PD modeling data for its investigational drug PIKTOR at the upcoming STOP Cancer conference. This data will inform the dose selection for the ongoing FTH-PIK-201 trial. The conference is scheduled for August 7-8, 2026, in New York, highlighting the company's commitment to oncology research.
Read more →-FTH
Aug 4, 2026▼ -6.7%on this newsshared move
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics announced its financial results for the second quarter of 2026, showcasing key corporate achievements and future milestones. The CEO, Anand Parikh, emphasized the significance of their recent collaboration with Sensei Biotherapeutics. This partnership is viewed as a pivotal moment for the company's growth and development in oncology.
Read more →-FTH
Jun 15, 2026Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Sensei Biotherapeutics has officially changed its corporate name to Faeth Therapeutics, with new trading under the ticker FTH beginning June 16, 2026. The company is advancing PIKTOR, an oral therapy targeting the PI3K/AKT/mTOR pathway, aiming for Phase 2 data in advanced endometrial cancer by the latter half of 2026. The leadership team has been strengthened with new appointments to guide the company through upcoming clinical trials. This pivot follows stockholder approval of a significant private placement, providing the necessary funding for these initiatives.
Read more →-FTH
May 21, 2026SENSEI BIOTHERAPEUTICS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION On
On February 17, 2026, Sensei Biotherapeutics, Inc. completed the acquisition of Faeth Holdings Therapeutics, Inc. and its subsidiary, which is expected to enhance its operational capabilities. Concurrently, the company raised $200 million in gross proceeds through a Securities Purchase Agreement with investors. The issuance of Series B Preferred Stock is set to convert into common stock following stockholder approval scheduled for June 10, 2026. The company provided unaudited pro forma condensed financial information reflecting the anticipated changes from these transactions.
Read more →-FTH
May 15, 2026Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer
Sensei Biotherapeutics has reported its financial results for the first quarter of 2026, highlighting the dosing of the first patient in a Phase 1b/2 trial of the cancer therapy PIKTOR. The company has acquired Faeth Therapeutics, enabling enhanced capital and progress towards clinical milestones. Despite a significant net loss of $170.2 million and increased research expenses, management is optimistic about the potential of PIKTOR in treating advanced cancers.
Read more →-FTH
Mar 30, 2026Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway
Sensei Biotherapeutics reported its financial results for the year ended December 31, 2025, highlighting the acquisition of Faeth Therapeutics and the associated $200 million private placement to support the development of PIKTOR. This investigational product aims to target multiple nodes of the PI3K/AKT/mTOR pathway in treatments for endometrial and breast cancer. While the company's R&D expenses decreased, they still reported a net loss of $21.1 million, though improved from the previous year's loss. The company remains focused on advancing PIKTOR through key clinical milestones expected by the end of 2026.
Read more →-FTH
Feb 18, 2026Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Sensei Biotherapeutics has announced its acquisition of Faeth Therapeutics, alongside a concurrent $200 million private placement. This strategic move is aimed at enhancing Sensei's pipeline, particularly with PIKTOR, a multi-node inhibitor designed to target solid tumors like endometrial and breast cancer. The funding will primarily support key clinical trials, including an ongoing Phase 2 trial for advanced endometrial cancer. Additionally, the acquisition is structured as a stock-for-stock transaction, significantly changing the equity landscape of Sensei post-acquisition.
Read more →-FTH
Nov 14, 2025Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Sensei Biotherapeutics reported its financial results for Q3 2025, highlighting the discontinuation of its lead product, solnerstotug. The company is currently exploring strategic alternatives, which may involve asset sales or a potential merger, while reducing its workforce by 65%. A review of the company's development pipeline has led to this decision amid unfavorable market conditions, resulting in a notable decrease in cash and substantial net losses. The company's cash and cash equivalents dropped significantly to $25 million, raising concerns about its financial viability.
Read more →-FTH
Oct 30, 2025Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
Sensei Biotherapeutics has announced the discontinuation of its solnerstotug development and is initiating a strategic review to explore alternatives for maximizing shareholder value. The company is considering several options, including asset sales, licensing, or potential mergers while planning a significant workforce reduction. The decision follows a careful evaluation of the company's pipeline and market conditions, and the future of its ongoing clinical trials now hangs in the balance.
Read more →-FTH
Oct 17, 2025Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Sensei Biotherapeutics has reported promising clinical results for solnerstotug in PD-(L)1 resistant tumors at the ESMO Congress 2025. A 50% 6-month progression-free survival rate was observed in the 15 mg/kg cohort, significantly higher than historical rates for similar treatments. The drug demonstrated a favorable safety profile, with mild cytokine release syndrome reported. Plans for Phase 2 trials are underway to further evaluate solnerstotug's efficacy in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
Read more →-FTH
Aug 5, 2025Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics reported its financial results for Q2 2025, highlighting a transition in its phase 1/2 study of solnerstotug towards data expected by year-end 2025. The company noted a favorable safety profile for solnerstotug, particularly in combination with cemiplimab. Financially, Sensei has sufficient cash to fund operations into Q2 2026, although it faced a net loss of $4.9 million. The firm plans to advance multiple Phase 2 studies to target PD-(L)1 resistant tumors, aiming to tap into significant market opportunities.
Read more →About Faeth Therapeutics, Inc. Common Stock
Headquarters701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
BIOPHARMAWATCH ELITE PLUS
Trade the next FTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime